Squarepoint
IMMX icon

Squarepoint’s Immix Biopharma IMMX Stock Holding History

Squarepoint’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$722K Buy
70,062
+25,572
+57% +$237K ﹤0.01% 3150
2026
Q1 		$405K Buy
44,490
+22,990
+107% +$169K ﹤0.01% 3473
2025
Q4 		$112K Buy
+21,500
New +$88.5K ﹤0.01% 4017
2024
Q3 		– Sell
-23,010
Closed -$45.6K – 4369
2024
Q2 		$45.6K Buy
+23,010
New +$52.9K ﹤0.01% 3912

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Squarepoint's IMMX Position: Q2 2026 in Review

Squarepoint increased its Immix Biopharma (IMMX) stake by 57% in Q2 2026, buying an estimated $237K and bringing the position to 70,062 shares worth $722K. The position accounts for ﹤0.01% of the portfolio, ranked #3150.

Squarepoint first reported a position in IMMX in Q2 2024 and has held it in 4 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Squarepoint held 70,062 shares of Immix Biopharma worth $722K as of Q2 2026.
  • Squarepoint bought 25,572 Immix Biopharma shares in Q2 2026, an estimated $237K.
  • Immix Biopharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3150 holding.
  • Squarepoint first reported a position in Immix Biopharma in Q2 2024 and has held it in 4 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.